Acrivon Therapeutics
Acrivon Therapeutics is a clinical stage oncology company leveraging its proprietary precision medicine platform, AP3, to develop targeted cancer therapies and companion diagnostics. The company focuses on matching therapies with patients most likely to benefit, using its unique OncoSignature tests to link tumor mechanisms with drug modes of action. Its pipeline includes the Phase 2 lead program ACR-368, a CHK1/2 inhibitor, and other proprietary programs targeting cell cycle and kinase pathways.
Industries
Nr. of Employees
medium (51-250)
Acrivon Therapeutics
US: Watertown, MA, 480 Arsenal Way, Suite 100, Watertown, MA 02472; Scandinavia: Lund, Sweden, Acrivon AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden
Patents
Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor
US-12433888-B1
View Details
Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor
US-12433888-B1
View DetailsProducts
Proteomics-based precision medicine platform
A platform that uses proteomics and phosphoproteomics to create diagnostic signatures linking tumor signaling states to drug mode-of-action for patient selection.
Spatial/multiplex companion diagnostic assays
Spatially-resolved proteomic/multiplex immunofluorescence assays intended to identify likely responders to specific oncology therapeutics for use in clinical trials.
Clinical-stage and preclinical small-molecule oncology programs
Development portfolio including a clinically active CHK1/2 inhibitor, an internally developed selective dual WEE1/PKMYT1 inhibitor clinical candidate, and a preclinical cell-cycle program.
Proteomics-based precision medicine platform
A platform that uses proteomics and phosphoproteomics to create diagnostic signatures linking tumor signaling states to drug mode-of-action for patient selection.
Spatial/multiplex companion diagnostic assays
Spatially-resolved proteomic/multiplex immunofluorescence assays intended to identify likely responders to specific oncology therapeutics for use in clinical trials.
Clinical-stage and preclinical small-molecule oncology programs
Development portfolio including a clinically active CHK1/2 inhibitor, an internally developed selective dual WEE1/PKMYT1 inhibitor clinical candidate, and a preclinical cell-cycle program.
Services
End-to-end development and clinical validation of spatial and proteomic companion diagnostic assays to stratify patients for biomarker-driven oncology trials.
Preclinical through Phase 2 development of small-molecule oncology therapeutics, including translational pharmacology, clinical trial execution and regulatory interactions.
Assessment and execution of in-licensing and partnership opportunities to acquire or co-develop oncology therapeutics and diagnostics.
End-to-end development and clinical validation of spatial and proteomic companion diagnostic assays to stratify patients for biomarker-driven oncology trials.
Preclinical through Phase 2 development of small-molecule oncology therapeutics, including translational pharmacology, clinical trial execution and regulatory interactions.
Assessment and execution of in-licensing and partnership opportunities to acquire or co-develop oncology therapeutics and diagnostics.
Expertise Areas
- Precision proteomics and spatial proteomics
- Companion diagnostic development and clinical validation
- Biomarker discovery and translational assay development
- Biostatistics and clinical study design
Key Technologies
- Phosphoproteomics
- Mass spectrometry-based proteomics
- Spatial proteomics imaging
- Multiplex immunofluorescence assays